MediWound Ltd Total Liabilities

Latest as of December 2025: €42.62 Million EUR ≈ $49.83 Million USD

MediWound Ltd total liabilities. Based on the latest financial reports, MediWound Ltd (M8W) has total liabilities worth €42.62 Million EUR (≈ $49.83 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MediWound Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of MediWound Ltd (2016–2025)

Total liabilities of MediWound Ltd from 2016 to 2025. This chart illustrates how MediWound Ltd's total liabilities have evolved over time, based on quarterly financial data.

MediWound Ltd Competitors by Total Liabilities

The table below lists competitors of MediWound Ltd ranked by their total liabilities.

Company Country Total Liabilities
AYM Syntex Limited
NSE:AYMSYNTEX
India Rs4.83 Billion
Yeo Teknoloji Enerji ve Endustri AS
IS:YEOTK
Turkey TL16.00 Billion
Indian Hume Pipe Company Limited
NSE:INDIANHUME
India Rs13.19 Billion
AGILYX ASA NK -02
F:5NQ
Germany €76.24 Million
AMA Group Limited
F:KC7
Germany €652.96 Million
Bygg Partner i Dalarna Holding AB
ST:BYGGP
Sweden Skr1.41 Billion
ARKO Petroleum Corp.
NASDAQ:APC
USA $1.13 Billion
Latécoère S.A.
PA:LAT
France €542.60 Million

Liability Composition Analysis (2016–2025)

This chart breaks down MediWound Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is MediWound Ltd's balance sheet.

Liquidity & Leverage Metrics

MediWound Ltd Total Liabilities Ratios Explained

MediWound Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.33 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.98 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.49 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how MediWound Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for MediWound Ltd (2016–2025)

The table below shows the annual total liabilities of MediWound Ltd from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 €42.62 Million
≈ $49.83 Million
+0.66%
2024-12-31 €42.34 Million
≈ $49.50 Million
+21.45%
2023-12-31 €34.86 Million
≈ $40.76 Million
-10.84%
2022-12-31 €39.10 Million
≈ $45.71 Million
+60.74%
2021-12-31 €24.33 Million
≈ $28.44 Million
+2.22%
2020-12-31 €23.80 Million
≈ $27.82 Million
-6.38%
2019-12-31 €25.42 Million
≈ $29.72 Million
-3.36%
2018-12-31 €26.30 Million
≈ $30.75 Million
-23.79%
2017-12-31 €34.52 Million
≈ $40.35 Million
+23.29%
2016-12-31 €27.99 Million
≈ $32.73 Million
--

About MediWound Ltd

F:M8W Germany Biotechnology
Market Cap
$175.80 Million
€150.37 Million EUR
Market Cap Rank
#16831 Global
#1592 in Germany
Share Price
€11.70
Change (1 day)
+1.74%
52-Week Range
€10.40 - €17.00
All Time High
€19.60
About

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn cen… Read more